← Eichor
Study identifier: NCT06177977 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

Condition: Retinal Dystrophies  ·  Sponsor: Duke University

PhaseNA
Planned participants80
Who can joinAll sexes, 0 Years to 8 Years
Healthy volunteersYes

About this study

The goal of this observational study is to utilize a novel imaging system designed for high-resolution retinal imaging of neonates, infants and children to identify the signs of photoreceptor development and degeneration in children with early-onset inherited retinal dystrophies (EORDs). Participants will have research imaging with SS-HH-OCT at the time of clinically-indicated eye examinations or procedures. The investigators aim to establish the basis for utilization of OCT imaging in earlier diagnosis and disease monitoring in children with EORDs. This work will set data reference standards and IRD endpoints that can be used in clinical trials.

This description comes directly from the study's public registry record.

Talk to the study team

Ramiro Maldonado, MD  ·  (919) 684 5631  ·  ramiro.maldonado@duke.edu

Michelle N McCall, MCAPM, BA  ·  (919) 684-0544  ·  michelle.mccall@duke.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Duke University Eye CenterDurham, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06177977